Thalitone Related Published Studies
Well-designed clinical trials related to Thalitone (Chlorthalidone)
Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. [2009.10]
Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. [2009.07.22]
A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. [2009.07]
Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. [2009.04]
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.05]
Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. [2006.03]
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. [2005.04.06]
Well-designed clinical trials possibly related to Thalitone (Chlorthalidone)
The effect of antihypertensive agents on sleep apnea: protocol for a randomized
controlled trial. [2014]
Blood pressure control and cardiovascular outcomes in normal-weight, overweight,
and obese hypertensive patients treated with three different antihypertensives in
ALLHAT. [2014]
Clinical significance of incident hypokalemia and hyperkalemia in treated
hypertensive patients in the antihypertensive and lipid-lowering treatment to
prevent heart attack trial. [2012]
Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. [2011.03.05]
A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. [2011.02.24]
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. [2011.02]
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in
relation to antihypertensive treatment: the genetics of hypertension associated
treatment study. [2011]
Antioxidative effects of thiazide diuretics in refractory hypertensive patients. A randomized crossover trial of chlortalidone and trichlormethiazide. [2010]
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). [2009.11.24]
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? [2009.09]
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. [2009.06]
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. [2009.05.11]
Changes in serum potassium mediate thiazide-induced diabetes. [2008.12]
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2008.11.25]
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.10]
Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. [2008.03]
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.28]
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]
Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. [2007.11]
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. [2007.01]
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. [2007]
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.11.13]
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.09]
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. [2006.02.07]
Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. [2005.06.28]
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.06.27]
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2005.04.25]
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. [2005.04]
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. [2005.01.01]
Other research related to Thalitone (Chlorthalidone)
Efficacy of azilsartan medoxomil with chlorthalidone in hypertension. [2014]
Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit
variability of blood pressure: results from the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2014]
Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination
antihypertensive. [2013]
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin
resistance in hypertensive patients. [2012]
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan
medoxomil and chlorthalidone: a factorial study. [2012]
Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular
events: systematic review and network meta-analyses. [2012]
Long-Term Effects of Chlorthalidone Versus Hydrochlorothiazide on Electrocardiographic Left Ventricular Hypertrophy in the Multiple Risk Factor Intervention Trial. [2011.12]
Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats. [2011.08]
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. [2011.04]
Association between chlorthalidone treatment of systolic hypertension and
long-term survival. [2011]
Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. [2010.12]
Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. [2010.04]
Hydrochlorothiazide versus chlorthalidone in the management of hypertension. [2010.01]
[Chlorthalidone better than hydrochlorothiazide in hypertension] [2010]
Development and validation of a reversed-phase high-performance liquid chromatographic method for the simultaneous determination of amiloride hydrochloride, atenolol, hydrochlorothiazide, and chlorthalidone in their combined mixtures. [2009.03]
DIFFERENTIAL EFFECTS OF CHLORTHALIDONE VS. SPIRONOLACTONE ON MUSCLE SYMPATHETIC NERVE ACTIVITY IN HYPERTENSIVE PATIENTS. [2009.01.21]
Should chlorthalidone be the diuretic of choice for antihypertensive therapy? [2008.08]
Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. [2008.06]
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.02]
Chlorthalidone inhibits the KvLQT1 potassium current in guinea-pig ventricular myocytes and oocytes from Xenopus laevis. [2008.02]
Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.29]
Metabolic and Clinical Outcomes in Non-Diabetic Individuals with the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A Report from the ALLHAT Study. [2007.11.13]
Drug-induced acute myopia following chlorthalidone treatment. [2007.09]
Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. [2005.12]
Other possibly related research studies
Survival of severe amlodipine intoxication due to medical intensive care. [2006.09.12]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2006.05.16]
Thiazide diuretics in the treatment of hypertension: an update. [2006.04]
Role of angiotensin II receptor blockers in atherosclerotic plaque stability. [2006.02]
[Diuretic therapy in heart failure] [2006.01]
Does ALLHAT change the management of hypertension in chronic kidney disease? [2005.12]
An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. [2005.09]
ALLHAT in perspective: implications to clinical practice and clinical trials. [2005.06]
Systemic hypertension. [2007.04]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.03]
Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000. [2006.10]
Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. [2007.01]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.04]
Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. [2007.06.30]
[Antihypertensive therapy and renoprotection: do we really need to block the renin-angiotension system?] [2007.09]
Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. [2007.10]
Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. [2008.04]
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. [2008.01.23]
Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic. [2007]
Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. [2008.06]
Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. [2008]
Resistant hypertension and hyperaldosteronism. [2008.12]
Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. [2009.07]
Diuretics: still essential drugs for the management of hypertension. [2009.06]
Improvement of diastolic function after regression of left ventricular hypertrophy. [2008.10]
[Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension] [2008.06]
The Evidence-Based Use of Thiazide Diuretics in Hypertension and Nephrolithiasis. [2010.08.26]
Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? [2010.08.25]
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. [2010.10]
Treatment of resistant hypertension. [2009.12]
[When do combinations of diuretics make sense?] [2009.11]
The Association between Hypertension and Dementia in the Elderly. [2012]
Long-Term follow-up of participants with heart failure in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2011.10.25]
Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. [2011.10]
Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. [2011]
[Why do good drugs disappear?]. [2010.10]
Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. [2011.04.15]
The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. [2010.10]
Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? [2011.09]
|